Clinical trials: Cryptogenic Stroke
Foramen Ovale, Patent
The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness
The primary objective of this study is to demonstrate the safety and efficacy of the PFX Closure System when utilized for patent foramen ovale (PFO) in patients suffering from cryptogenic stroke (undetermined cause of stroke)…
- Trial name
- NCT00196040
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Cierra
Cryptogenic Stroke, Atrial Fibrillation
Atrial Tachycardia as a Predictor of Atrial Fibrillation, Stroke and Mortality in Cryptogenic Stroke
There is few information about the association between supraventricular arrhythmia different from atrial fibrillation (AF) or atrial Flutter and the risk of stroke.
- Conditions
- Cryptogenic Stroke, Atrial Fibrillation, Atrial Tachycardia
- Trial name
- NCT02374359
- Testing
- follow-up
- Where
- Spain
- Volunteers
- 210 people
- Sponsor
- Corporacion Parc Tauli
Stroke
Finding Atrial Fibrillation in Patients With Unexplained Stroke Using Longterm Cardiac Monitoring
The SURPRISE study investigates atrial fibrillation(AFIB) in patients with a previous unexplained stroke. It uses long term monitoring of the heart of up to three years, searching for paroxysmal atrial fibrillation(PAF) otherwise…
- Trial name
- SURPRISE (NCT01498146)
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- Bispebjerg Hospital
Cryptogenic Embolic Stroke, Active Cancer
Identification the Cause of Cerebral Infarction in Patients With Cancer
Although there has been increasing interest in the association between cancer and cerebrovascular disease, the underlying pathophysiology of stroke in cancer patients is still not fully understood.
- Trial name
- NCT02212496
- Where
- South Korea
- Volunteers
- 118 people
- Sponsor
- Samsung Medical Center
Cryptogenic Stroke, Foramen Ovale, Patent
Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study
The aim of the ALFA ROMEO study is to better understand the association between cryptogenic stroke, PFO, PFO closure and AF.
- Conditions
- Cryptogenic Stroke, Foramen Ovale, Patent, Atrial Fibrillation
- Trial name
- ALFA-ROMEO (NCT04881578)
- Testing
- continuous cardiac monitoring before and after transcatheter PFO closure
- Where
- 6 sites in Switzerland
- Volunteers
- 200 people
- Sponsor
- Raban Jeger
Stroke, Foramen Ovale, Patent
Prospective Clinical Follow-up After the Percutaneous Closure of a Patent Foramen Ovale
Following a cryptogenic stroke, many patients are nowadays treated with the percutaneous closure of a patent foramen ovale (PFO), assuming that the aetiology of the stroke is secondary to a paradoxical embolism.
- Trial name
- PFO-HUG (NCT01149447)
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University Hospital, Geneva
Patent Foramen Ovale, Cryptogenic Stroke
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
To evaluate the performance of Cera™ patent foramen ovale occluders developed by Lifetech Scientific (Shenzhen) Co., LTD;
- Trial name
- NCT05774288
- Testing
- Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders
- Where
- 14 sites in China
- Volunteers
- 244 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Cryptogenic Stroke or TIA, Atrial Fibrillation
Detection of Occult Paroxysmal AF in Cryptogenic Stroke or TIA Patients Using an Implantable Loop Recorder and Correlation With Genetic Markers.
Atrial fibrillation (AF) is the significant risk factor of ischemic stroke with incidence about 20% of all ischemic strokes. The undiagnosed AF in cryptogenic stroke patients could be present but not revealed by rutinne ECG.
- Trial name
- NCT02216370
- Where
- Slovakia
- Volunteers
- 125 people
- Sponsor
- University Hospital, Martin
Apnea Syndrome, Stroke
Relationship Between Sleep Apnea Syndrome and Patent Foramen Ovale Among Victims of Cryptogenic Ischemic Stroke
Obstructive sleep apnea syndrome (OSAS) and patent foramen ovale (FOP) are considered as risk factors for stroke. OSAS generates a pressure increase in the right cavity during inspiratory efforts, which increases the number of…
- Trial name
- NCT04846205
- Testing
- systematic etiological
- Where
- France
- Volunteers
- 159 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Suspected Arrhythmia, Palpitations
This Exploratory Medical Device Study Evaluated the Arrhythmia Diagnostic Yield of MEMO Patch V2, a Wearable Patch-type Electrocardiographic Monitor, in Adults With Suspected Arrhythmia Who Presented With Symptoms Such as Palpitations or Dizziness, or Who Had Cryptogenic Ischemic Stroke or Transient
This exploratory medical device study evaluated the arrhythmia diagnostic yield of MEMO Patch V2, a wearable patch-type electrocardiographic monitor, in adults with suspected arrhythmia who presented with symptoms such as…
- Conditions
- Suspected Arrhythmia, Palpitations, Dizziness, Cryptogenic Ischemic Stroke
- Trial name
- NCT07722026
- Testing
- MEMO Patch V2, 24-Hour Holter Monitor
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- HUINNO Co., Ltd
Stroke
Atrial Fibrillation After PFO Closure
An increased risk of atrial fibrillation (AF) after patent foramen ovale (PFO) closure was observed in randomized trials but systematic screening of AF was not performed in these studies.
- Trial name
- AFEPFO (NCT04290052)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Ischemic Stroke, Cryptogenic, Transient Ischemic Attack
Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke
Scientific Background: In secondary prevention of ischemic stroke, detection of atrial fibrillation (AFib) and subsequent anticoagulation therapy reduce the risk of recurrent stroke by approximately 60%.
- Conditions
- Ischemic Stroke, Cryptogenic, Transient Ischemic Attack, Atrial Fibrillation
- Trial name
- WATCH AFib (NCT06005233)
- Testing
- Smartwatch
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Technical University of Munich
Permeable Foramen Ovale, Cerebrovascular Accident
Interest of Occlusion of Permeable Foramen Ovale After a Cryptogenic Cerebrovascular Accident (CVA)
Facing the lack of recommandations of Neurology and cardiology societies, the investigators decided in 2002 some Good Medical Practices to define a specific and precise population for whom the closure of permeable oval formaen…
- Trial name
- FOPasa (NCT00872443)
- Testing
- Data collection
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Nantes University Hospital
Embolic Stroke of Undetermined Source
Registry Study for the Observation of Patients With ESUS/Cryptogenic Stroke
Up to know, there is no clear diagnostic and therapeutic pathway for patients with embolic stroke of undetermined source (ESUS).
- Trial name
- Catch-up-ESUS (NCT03820375)
- Where
- Germany
- Volunteers
- 750 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Stroke, Atrial Fibrillation
Monitoring Strategies for the Detection of Atrial Fibrillation in Patients with Cryptogenic Stroke
Randomized clinical trial comparing two monitoring strategies, the use of a 48-hour Holter (routine care branch) and an event recorder for 7 days (intervention branch). Patients admitted for cryptogenic stroke will be included.
- Trial name
- NCT04644679
- Testing
- 7-day electrocardiographic monitoring, 48-hr electrocardiographic monitoring
- Where
- Argentina
- Volunteers
- 49 people
- Sponsor
- Hospital Italiano de Buenos Aires
Patent Foramen Ovale, Stroke
Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)
The primary objective of the study is to determine whether the STARFlex® septal closure system will safely and effectively prevent a recurrent embolic stroke/transient ischemic attack (TIA) and mortality in patients with a PFO…
- Conditions
- Patent Foramen Ovale, Stroke, Ischemic Attack, Transient
- Trial name
- NCT00201461
- Testing
- STARFlex septal closure system, Best medical therapy
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- NMT Medical
Annexin A2, Stroke
Genetic Variants of Annexin A2 and Cryptogenic Stroke
Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an…
- Conditions
- Annexin A2, Stroke, Genetic Variants of Host, Fibrinolysis
- Trial name
- GENANXVA (NCT06880107)
- Testing
- blood withdrawal
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Stroke, PFO - Patent Foramen Ovale
The PROOF Trial - Prospective, Open-label, Multicenter, Non-randomized Investigation on Percutaneous Patent Foramen Ovale (PFO) Closure Using the Occlutech PFO Occluder to Prevent Recurrence of Stroke in Patients With Cryptogenic Stroke and High Risk PFO
Percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients who have had a cryptogenic stroke due to a presumed paradoxical embolism.
- Trial name
- PROOF (NCT04029233)
- Testing
- Occlutech PFO Occluder
- Where
- 17 sites in Canada, France and 2 more
- Volunteers
- 582 people
- Sponsor
- Occlutech International AB
Occult Cancer
Intensive Cancer Screening After Cryptogenic Stroke
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening…
- Trial name
- INCOGNITO (NCT05733416)
- Testing
- FDG PET/CT, Usual Care
- Where
- 3 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Ottawa Hospital Research Institute
Patent Foramen Ovale (PFO)
Non-Invasive Detection of Right-to-Left Cardiac Shunts
This study will test the sensitivity of a novel, battery-powered, non-invasive ultrasound device to detect a right-to-left shunt
- Trial name
- HEADBAND (NCT07420400)
- Testing
- Point-of-care ultrasound
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Scripps Health